<![CDATA[FDA Accepts Priority Review for Dostarlimab in dMMR/MSI-H Rectal Cancer]]>

NDA FilingdostarlimabPositive

AI Analysis

Summary

The FDA accepted a priority review application for dostarlimab in untreated dMMR/MSI-H locally advanced rectal cancer, supported by AZUR-1 trial data.

Clinical Trial Data

Outcome Details

FDA accepted priority review application

Importance:7/10

Sentiment:

0.70

FDApriority reviewrectal cancerdMMRMSI-HAZUR-1

Related Companies

$GMAB

Read the original article

Published by Cancer Network on August 24, 2026 4:00 PM

Read Original